ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control and adding savory flavors are ways that ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

HS-10535 is a glucagon-like peptide (GLP)-1 analog under development as an oral medication, similar to Novo Nordisk's Wigov. Merck is also collaborating with another Chinese corporation to license an ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Polypeptides such as glucagon-like peptide-1 (GLP-1) analogue used to prevent obesity represents a new direction for drug design, but with poor adherence of patients to injectable therapies. Oral ...

The NHS had been facing supply issues with glucagon-like peptide receptor agonists (GLP-1 RAs, or GLP-1 analogues), a range of drugs used for managing blood glucose levels in people with type 2 ...

Excluding people with type 2 diabetes from the trial might have resulted in a missed opportunity to establish whether people with both Parkinson's disease and type 2 diabetes could benefit from GLP-1 ...